Marked increase of procalcitonin after the administration of anti-thymocyte globulin in patients before hematopoietic stem cell transplantation does not indicate sepsis: a prospective study

被引:50
作者
Brodska, Helena [1 ,2 ,3 ]
Drabek, Tomas [1 ,4 ]
Malickova, Karin [1 ,2 ,3 ]
Kazda, Antonin [1 ,2 ,3 ]
Vitek, Antonin [1 ,5 ]
Zima, Tomas [1 ,2 ,3 ]
Markova, Marketa [1 ,5 ]
机构
[1] Charles Univ Prague, Fac Med 1, CZ-12108 Prague 2, Czech Republic
[2] Gen Teaching Hosp, Inst Clin Biochem, CZ-12108 Prague 2, Czech Republic
[3] Gen Teaching Hosp, Diagnost Lab, CZ-12108 Prague 2, Czech Republic
[4] Univ Pittsburgh, Dept Anesthesiol, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA
[5] Inst Hematol & Blood Transfus, CZ-12820 Prague 2, Czech Republic
来源
CRITICAL CARE | 2009年 / 13卷 / 02期
关键词
C-REACTIVE PROTEIN; SERUM-LEVELS; EXPRESSION; INFECTION; LIVER;
D O I
10.1186/cc7749
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Introduction Procalcitonin (PCT) and C-reactive protein (CRP) are established markers of infection in the general population. In contrast, several studies reported falsely increased PCT levels in patients receiving T-cell antibodies. We evaluated the validity of these markers in patients scheduled for hemopoietic stem cell transplantation receiving anti-thymocyte globulin (ATG) during conditioning. We also assessed renal and liver functions and their relationship to PCT and CRP changes. Methods Twenty-six patients without clinical signs of infection were prospectively studied. ATG was administered in up to three doses over the course of 5 days. PCT, CRP, white blood cell (WBC) count, urea, creatinine, glomerular filtration rate, bilirubin, alanin amino-transferase (ALT), and gamma-glutamyl transferase (GGT) were assessed daily during ATG administration. Pharyngeal, nose, and rectal swabs and urine samples were cultured twice weekly. Blood cultures were obtained if clinical symptoms of infection were present. Results Baseline (BL) levels of both PCT and CRP before ATG administration were normal. WBC count decreased after ATG administration (P = 0.005). One day after ATG administration, both PCT and CRP levels increased significantly, returning to BL levels on day 4. Microbiological results were clinically unremarkable. There was no interrelationship between PCT levels and BL markers of renal or liver functions (P > 0.05 for all comparisons). Bilirubin and GGT were increased on days 2 to 5 and ALT was increased on day 3 (P < 0.05 versus BL). No difference in renal functions was observed. Three patients developed bacterial infection on days 7 to 11 with different dynamics of PCT and CRP. There was no association between the number of ATG doses and PCT levels or between the risk of developing infection and previous PCT levels. Conclusions ATG triggered a marked early surge in PCT and CRP followed by a steady decrease over the course of 3 days. The dynamics of both PCT and CRP were similar and were not associated with infection. PCT levels were independent of renal and liver functions and were not predictive of further infectious complications. A direct effect of ATG on T lymphocytes could be the underlying mechanism. Hepatotoxic effect could be a contributing factor. Neither PCT nor CRP is a useful marker that can identify infection in patients receiving ATG.
引用
收藏
页数:7
相关论文
共 25 条
[1]  
Assumma M, 2000, CLIN CHEM, V46, P1583
[2]  
Bolko P, 2003, ARCH IMMUNOL THER EX, V51, P415
[3]   AMERICAN-COLLEGE OF CHEST PHYSICIANS SOCIETY OF CRITICAL CARE MEDICINE CONSENSUS CONFERENCE - DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ ;
ABRAMS, JH ;
BERNARD, GR ;
BIONDI, JW ;
CALVIN, JE ;
DEMLING, R ;
FAHEY, PJ ;
FISHER, CJ ;
FRANKLIN, C ;
GORELICK, KJ ;
KELLEY, MA ;
MAKI, DG ;
MARSHALL, JC ;
MERRILL, WW ;
PRIBBLE, JP ;
RACKOW, EC ;
RODELL, TC ;
SHEAGREN, JN ;
SILVER, M ;
SPRUNG, CL ;
STRAUBE, RC ;
TOBIN, MJ ;
TRENHOLME, GM ;
WAGNER, DP ;
WEBB, CD ;
WHERRY, JC ;
WIEDEMANN, HP ;
WORTEL, CH .
CRITICAL CARE MEDICINE, 1992, 20 (06) :864-874
[4]   Kinetics of procalcitonin in iatrogenic sepsis [J].
Brunkhorst, FM ;
Heinz, U ;
Forycki, ZF .
INTENSIVE CARE MEDICINE, 1998, 24 (08) :888-889
[5]   Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction [J].
Castelli, GP ;
Pognani, C ;
Meisner, M ;
Stuani, A ;
Bellomi, D ;
Sgarbi, L .
CRITICAL CARE, 2004, 8 (04) :R234-R242
[6]   Non-infectious causes of elevated procalcitonin and C-reactive protein serum levels in pediatric patients with hematologic and oncologic disorders [J].
Dornbusch, Hans Juergen ;
Strenger, Volker ;
Sovinz, Petra ;
Lackner, Herwig ;
Schwinger, Wolfgang ;
Kerbl, Reinhold ;
Urban, Christian .
SUPPORTIVE CARE IN CANCER, 2008, 16 (09) :1035-1040
[7]   Procalcitonin and C-reactive protein do not discriminate between febrile reaction to anti-T-lymphocyte antibodies and Gram-negative sepsis [J].
Dornbusch, HJ ;
Strenger, V ;
Kerbl, R ;
Lackner, H ;
Schwinger, W ;
Sovinz, P ;
Urban, C .
BONE MARROW TRANSPLANTATION, 2003, 32 (09) :941-945
[8]   Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia:: experience from a multicentre study [J].
Giamarellou, H ;
Giamarellos-Bourboulis, EJ ;
Repoussis, P ;
Galani, L ;
Anagnostopoulos, N ;
Grecka, P ;
Lubos, D ;
Aoun, M ;
Athanassiou, K ;
Bouza, E ;
Devigili, E ;
Krçmery, V ;
Menichetti, F ;
Panaretou, E ;
Papageorgiou, E ;
Plachouras, D .
CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 (07) :628-633
[9]   Circulating procalcitonin and cleavage products in septicaemia compared with medullary thyroid carcinoma [J].
Ittner, L ;
Born, W ;
Rau, B ;
Steinbach, G ;
Fischer, JA .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2002, 147 (06) :727-731
[10]   Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia [J].
Jimeno, A ;
Garcia-Velasco, A ;
del Val, O ;
González-Billalabeitia, E ;
Hernando, S ;
Hernández, R ;
Sánchez-Muñoz, A ;
López-Martín, A ;
Durán, I ;
Robles, L ;
Cortés-Funes, H ;
Paz-Ares, L .
CANCER, 2004, 100 (11) :2462-2469